Taspoglutide is a former
experimental drug, a
glucagon-like peptide-1 agonist (GLP-1 agonist), that was under investigation for treatment of
type 2 diabetes and being codeveloped by
Ipsen and
Roche.
Initially, phase II trials reported it was effective and well tolerated.
Of the eight planned phase III clinical trials of weekly taspoglutide (four against
exenatide,
sitagliptin,
insulin glargine, and
pioglitazone), at least five were active in 2009. Preliminary results in early 2010 were favourable. (At least one of the eight planned phase III trials had not started recruiting by end 2009.)
In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects.
no new trials have been registered since 2010.
Clinical studies of taspoglutide
/ref>
Chemistry
Taspoglutide is the peptide with the sequence H2N-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH2.
In other words, it is the 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide derivative of the amino acid sequence 7–36 of human glucagon-like peptide I.
See also
* Incretin
References
Glucagon-like peptide-1 receptor agonists
Abandoned drugs
{{gastrointestinal-drug-stub